Kapitalradar

Swiss capital increases, read from the official gazette and scored for financing rounds.

updated every weekdayrelease r10data as of 8 Oct 2026

↺ Try a rewind: Soverli AG on 24 Sep 2025, 83 days before the round was announced
Latest available record · 8 Oct 2026

Release evaluation · 7 Oct 2026 · does not rewind · rules + Claude: precision 2%–100% (n=17), recall 16/30 announced rounds · rules-only: precision 1%–99% (n=29), recall 18/30 announced rounds · Methodology

Published by 21 Dec 2025
Drag the red line through time · ← → a day · Shift+← → a week. Later days aren’t drawn: they haven’t been published yet.
1733not yet publishedAug 25Sep 25Oct 25Nov 25Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26

Scope · likely financings by canton

57 likely financings · 22 Nov 2025 – 21 Dec 2025 · the feed below shows one weekBS ✕ show all cantonsMap: Natural Earth

Likely financing
Looks like new money from outside investors: Claude, reading the entry and the rule signals, scores it 0.60 or higher.
Undecided
Some financing signals, not enough to call it: a score from 0.35 to below 0.60, or no usable score.
Capital increased
No sign of a financing round: the pre-filter found nothing to send to Claude, or Claude scored it below 0.35. Typical causes are converted loans, assets contributed in kind, reserves turned into capital or a conversion to an AG.
Confirmed round
A financing announcement on startupticker.ch names the company and matches this increase.

Published 15–21 Dec 2025 · canton BS

6 capital increases · 2 shown
Showing: likely financings and confirmed rounds ▾
Show
Capital increases published 15–21 Dec 2025
CompanyStatusNominal share capital (CHF)
before → after		New shares, % of
post-step shares		Announced roundnot disclosed in the SHABSHAB publishedSource
FoRx Therapeutics AGBS · Die Gesellschaft bezweckt Erforschung, die Entwicklung, die Herstellung, die Verwertung, den Erwerb und den …SHAB publication HR02-1006517533Confirmed round · missed by classifierscore 0.40Announced round: USD 50’000’000 ↗1’735’902 → 3’678’634New shares 52.8%52.8%USD 50’000’000 ↗18 Dec 2025SHAB publication HR02-1006517533
Mosanna Therapeutics AGBS · Die Gesellschaft bezweckt die Entwicklung, Herstellung, und den Verkauf von pharmazeutischen und anderen …SHAB publication HR02-1006514524Likely financingscore 0.95557’482.38 → 742’684.57New shares 24.9%24.9%—16 Dec 2025SHAB publication HR02-1006514524

4 other capital increases published this week ▸